

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ANTARES PHARMA, INC., LEO PHARMA A/S AND
LEO PHARMA INC.
Petitioners

v.

MEDAC GESELLSCHAFT FÜR KLINISCHE
SPEZIALPRÄPARATE MBH
Patent Owner

Case No. IPR2014-01091
Patent Number 8,664,231

Before JACQUELINE WRIGHT BONILLA, *Administrative Patent Judge*

**PATENT OWNER'S PRELIMINARY RESPONSE
UNDER 37 C.F.R. § 42.107**

TABLE OF CONTENTS

I.	Introduction.....	1
II.	Overview Of The ‘231 Patent	8
III.	Background On The Treatment Of Inflammatory Autoimmune Diseases With Methotrexate.....	9
IV.	The Disclosure of the ‘231 Patent	13
V.	Claim Construction	19
VI.	The ‘231 Patent Claims Are Not Anticipated	20
A.	There Is No Reasonable Likelihood That <i>Grint</i> Anticipates Claims 1, 2, 4, 5, 6, 11, 12, 13, 17, and 20 (Ground 1).....	21
VII.	The ‘231 Patent Claims Would Not Have Been Obvious	27
A.	There Is No Reasonable Likelihood That <i>Grint</i> Renders Claims 7-10, 14-16, And 19-21 Obvious In View Of <i>Insulin Admin.</i> (Ground 2).....	28
B.	There Is No Reasonable Likelihood That <i>Grint</i> Renders Claim 18 Obvious In View Of <i>Alsufyani</i> (Ground 3).....	29
C.	There Is No Reasonable Likelihood That <i>The PDR for Mexate</i> [®] or <i>Hospira</i> Renders Claims 1-5, 11, 12, 13, 17, And 22 Obvious In View Of <i>Brooks</i> (Ground 4).....	30
D.	There Is No Reasonable Likelihood That <i>The PDR for Mexate</i> [®] Or <i>Hospira</i> Renders Claims 7-10, 14-16, And 19-21 Obvious In View Of <i>Brooks</i> And <i>Insulin Admin.</i> (Ground 5).....	38
E.	There Is No Reasonable Likelihood That <i>Hoekstra</i> Renders Claims 1-6, 11, 12, 13, 17, And 22 Obvious In View Of <i>Jorgensen</i> (Ground 6)	39
F.	There Is No Reasonable Likelihood That <i>Hoekstra</i> Renders Claims 7-10, 14-16, And 19-21 Obvious In View Of <i>Jorgensen</i> And <i>Insulin Admin.</i> (Ground 7)	41
G.	There Is No Reasonable Likelihood That <i>Hoekstra</i> Renders Claim 18 Obvious In View Of <i>Jorgensen</i> And <i>Alsufyani</i> (Ground 8)	41
VIII.	Secondary Considerations	42
IX.	Conclusion	42

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>In re Arkeley</i> , 455 F.2d 586, 587 (C.C.P.A. 1972)	22
<i>Net MoneyIN, Inc. v. VeriSign, Inc.</i> , 545 F.3d 1359, 1371 (Fed. Cir. 2008)	22
<i>Phillips v. AWH Corp.</i> , 415 F.3d 1303 (Fed. Cir. 2005)	19
<i>Sanofi-Synthelabo v. Apotex, Inc.</i> , 550 F.3d 1075 (Fed. Cir. 2008)	22, 24
<i>In re Suitco Surface, Inc.</i> , 603 F.3d 1255 (Fed. Cir. 2010)	19
<i>Warner Chilcott Labs. Ir., Ltd. v. Impax Labs., Inc.</i> , 2012 U.S. Dist. LEXIS 60386 (D.N.J. Apr. 30, 2012)	22
STATUTES	
35 U.S.C. § 102	3
35 U.S.C. § 314	1, 2, 7, 42
OTHER AUTHORITIES	
37 C.F.R. § 42.100(b)	19
37 C.F.R. § 42.107	1
37 C.F.R. § 42.108(c)	2
37 C.F.R. § 42.120	1, 20
77 Fed. Reg. 48680, 48694 (Aug. 14, 2012)	2

EXHIBITS

2001	British Society for Paediatric and Adolescent Rheumatology, "Methotrexate Patient Information Leaflet," St. Albans (2011)
2002	U.S. Patent No. 8,480,631 to Sadowski <i>et al.</i> , entitled "Hazardous Agent Injection System," filed September 7, 2012, issued July 9, 2013
2003	Breslin, <i>et al.</i> , "Improving Tolerance and Bioavailability of Methotrexate by Switching from Oral to Subcutaneous Route of Administration," <i>Rheumatology</i> 388 (2005)
2004	Schiff, <i>et al.</i> , "Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis," <i>Ann Rheum Dis</i> 0:1-3 (2014)
2005	ACR Minisymposium, Novel Approaches to Biological Response Modification in Rheumatoid Arthritis, Sunday, November 14, 1999, Weinblatt <i>et al.</i> rHUIL-10 (Tenovil) Plus Methotrexate (MTX) in Active Rheumatoid Arthritis (RA) Phase I/II Study
2006	Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 7th Ed, 1985, 1263-67
2007	U.S. Patent No. 5,593,671 to Kerwar <i>et al.</i> , entitled "Method of Attenuating Lung Capillary Leak in a Mammal," filed July 1, 1994, issued January 14, 1997
2008	Annotated version of U.S. Patent No. 6,544,504 to Grint <i>et al.</i> , entitled "Combined Use of Interleukin 10 and Methotrexate for Immunomodulatory Therapy," filed June 26, 2000, issued April 8, 2003
2009	Condit, The Acute Toxicity of Amethopterin in Man, <i>Cancer</i> , 13:222-228 (1960)
2010	Condit, The Duration of the Effects of the Folic Acid Antagonists in Man, <i>Cancer</i> , 13:229-235 (1960)
2011	Condit <i>et al.</i> , The Effect of Amethopterin on Erythropoiesis in Man, <i>Cancer</i> , 13:245-249 (1960)
2012	Bertino, Methotrexate: Clinical Pharmacology and Therapeutic Application, <i>Cancer and Chemotherapy</i> , 3:359-375 (1981)
2013	Evans, Methotrexate, <i>Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring</i> , 16:518-548 (1980)
2014	Jolivet <i>et al.</i> , The Pharmacology and Clinical Use of Methotrexate, <i>N. Engl. J. Med.</i> , 309:1094-1104 (1983)
2015	Product Insert for the "Methotrexate Injection, USP" product (10 mg/ml or 25 mg/ml) by Hospira, Inc., Lake Forest, IL 60045, Product of Australia (Revised October 2011)

2016	Hoekstra, <i>et al.</i> , Bioavailability of Higher Dose Methotrexate Comparing Oral and Subcutaneous Administration in Patients with Rheumatoid Arthritis, <i>J. Rheumatol</i> 31(4):645-648 (2004)
2017	Meier, <i>et al.</i> , “Biopharmazie: Theorie und Praxis der Pharmakokinetik,” Thieme Verlag, Stuttgart (1981)
2018	Product Insert for “Methotrexat,” manufactured by EBEWE Pharma Ges.m.b.H., A-4866 Unterach, Austria, available at http://www.old.health.gov.il/units/pharmacy/trufot/alonim/791.pdf
2019	Sasson, <i>et al.</i> , “Hypodermoclysis: An Alternative Infusion Technique,” <i>Am. Family Physician</i> , 64(9):1575-1578
2020	Balis, <i>et al.</i> , “Pharmacokinetics of Subcutaneous Methotrexate,” <i>Journal of Clinical Oncology</i> 6(12):1882-1886 (1988)
2021	Press Release by Antares Pharma, Inc., dated April 17, 2014, entitled “Drug-Exposure Limitations of Oral Methotrexate at Doses Greater Than or Equal to 15 mg May Be Overcome with Subcutaneous Administration.”

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.